Attempts to achieve an accurate noninvasive glucose monitor to date have been unsuccessful. The GWave device (Hagar, Israel) filters out the “white noise” and uses radiofrequency that detects capillary blood glucose across the physiological range. Measuring blood as opposed to interstitial fluid glucose, allows elimination of the “lag time” and poor accuracy seen in the first day of the current invasive continuous glucose monitors. Calibration of the GWave device is not required. Original data with the first prototype device revealed a 96% and 97% zone A (N = 53) in the Clarke Error Grid (CEG) comparing to venous and capillary blood, respectively. Initial results with second generation devices in non-diabetic subjects compared to capillary blood noted 99% in CEG Zone A and a MARD of 7.1% (N = 120 measurements) (Figure). These data were reproducible with two GWave devices (MARD 5.1%). Combining first and second-generation devices (N = 43 measurements) with a range of glucose of 69 to 400 mg/dL), CEG in Zone A was 98%. Subjects with both type 1 and type 2 diabetes are now being studied to examine accuracy at a wider physiological range of glycemia. Early results from the GWave glucose monitor shows promise as the first noninvasive technology. The current on-going studies will provide more insight for its use in diabetes care.


I. B. Hirsch: Consultant; Abbott Diabetes, Lifecare, Inc., Hagar, Research Support; Beta Bionics, Inc., Insulet Corporation, Dexcom, Inc. A. Navon: Consultant; GWave.


Hagar Technologies

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at